ArticleBMC musculoskeletal disorders2026
Development and evaluation of a modified injectable calcium phosphate cement with enhanced injectability and mechanical stability for bone defect repair.
Article in BMC musculoskeletal disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
This study aimed to optimize an injectable carbonated hydroxyapatite cement for metaphyseal bone defect filling and to evaluate its biomechanical performance in distal radius fracture fixation. Six food- or pharmaceutical-grade additives, including sodium alginate, glycerol, astragalus gum, xanthan gum, citric acid, and hydroxypropyl methylcellulose (HPMC), were screened to improve injectability while maintaining setting behavior and mechanical strength. Among them, 2% HPMC provided the best overall performance, increasing injectability to approximately 95% without markedly affecting setting time or compressive strength. The optimized injectable carbonated hydroxyapatite cement (ICHA) was then tested in a standardized human cadaveric distal radius fracture-defect model using three fixation strategies: K-wire fixation alone, ICHA cement alone, and combined ICHA + K-wire fixation. Within a 10° torsion range, the ICHA and ICHA + K-wire groups showed higher torsional stiffness and maximum torque than the K-wire-only group, although peak torque occurred at smaller torsion angles. Under physiological compression, the groups showed comparable stability, whereas ICHA-containing groups showed greater resistance under higher compression. These findings suggest that 2% HPMC-modified ICHA may serve as an injectable metaphyseal void filler and structural adjunct to conventional K-wire fixation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.